Regarding trial data, didn’t IPIX design the phase 2 for OM and UP in consultation with and/or input from the CDA people?
“These recent data, taken in aggregate, are what various actively engaged pharmaceutical companies have desired from us for some time—and they are what triggered a newfound flurry of inbound partnership discussions...”